Search research articles
Contact Us
Filters
Showing results (1051-1060 of 1,171) with videos related to
Page
of 118
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2017
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Lars D Engstrom, Ruth Aranda, Matthew Lee, et al.
Cell Reports
|
November 24, 2016
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer
Shawn F Johnson, Cristina Cruz, Ann Katrin Greifenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2016
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
Patricia M LoRusso, Jing Li, Angelika Burger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 5, 2020
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
A G Waks, O Cohen, B Kochupurakkal, et al.
The Lancet. Oncology
|
June 20, 2020
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 25, 2020
Incorporating Real-time Influenza Detection Into the Test-negative Design for Estimating Influenza Vaccine Effectiveness: The Real-time Test-negative Design (rtTND)
Leora R Feldstein, Wesley H Self, Jill M Ferdinands, et al.
MMWR. Morbidity and Mortality Weekly Report
|
September 11, 2020
Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities - United States, July 2020
Kiva A Fisher, Mark W Tenforde, Leora R Feldstein, et al.
JAMA Network Open
|
March 23, 2019
Analysis of Diagnoses, Symptoms, Medications, and Admissions Among Patients With Cancer Presenting to Emergency Departments
Jeffrey M Caterino, David Adler, Danielle D Durham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Atish D Choudhury, Celestia S Higano, Johann S de Bono, et al.
The Journal of Emergency Medicine
|
July 30, 2019
Validation of the Emergency Severity Index (Version 4) for the Triage of Adult Emergency Department Patients With Active Cancer
David Adler, Beau Abar, Danielle D Durham, et al.
Page
of 118
Search research articles
Search
Showing results (1051-1060 of 1,171) with videos related to
Sort By:
Page
of 118
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2017
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Lars D Engstrom, Ruth Aranda, Matthew Lee, et al.
Cell Reports
|
November 24, 2016
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer
Shawn F Johnson, Cristina Cruz, Ann Katrin Greifenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2016
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
Patricia M LoRusso, Jing Li, Angelika Burger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 5, 2020
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
A G Waks, O Cohen, B Kochupurakkal, et al.
The Lancet. Oncology
|
June 20, 2020
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 25, 2020
Incorporating Real-time Influenza Detection Into the Test-negative Design for Estimating Influenza Vaccine Effectiveness: The Real-time Test-negative Design (rtTND)
Leora R Feldstein, Wesley H Self, Jill M Ferdinands, et al.
MMWR. Morbidity and Mortality Weekly Report
|
September 11, 2020
Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities - United States, July 2020
Kiva A Fisher, Mark W Tenforde, Leora R Feldstein, et al.
JAMA Network Open
|
March 23, 2019
Analysis of Diagnoses, Symptoms, Medications, and Admissions Among Patients With Cancer Presenting to Emergency Departments
Jeffrey M Caterino, David Adler, Danielle D Durham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Atish D Choudhury, Celestia S Higano, Johann S de Bono, et al.
The Journal of Emergency Medicine
|
July 30, 2019
Validation of the Emergency Severity Index (Version 4) for the Triage of Adult Emergency Department Patients With Active Cancer
David Adler, Beau Abar, Danielle D Durham, et al.
Page
of 118